Pharma

Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million.

Kevin Dunleavy Jun 29, 2026 11:30am

FDA snubs Sobi’s gout drug over manufacturing issues

Jun 29, 2026 11:04am

Designing an agentic, future‑ready tech roadmap for emerging pharma

Brought to you by ZS

Regulatory tracker: FDA starts review of Sandoz's generic GLP-1

Jun 29, 2026 10:30am

Pharma marketers face privacy hurdles, turn to omnichannel strategies

Brought to you by Swoop

showdown clash versus vs crash lightning fight dispute

The Oral GLP-1 Tracker: Lilly works to build Foundayo awareness

Jun 29, 2026 9:15am